Promising 2022; even the softer 2023 guidance isn’t a worry
20/03/23 -"The positive recommendation is reiterated, underpinned by the firm’s strong pipeline, healthy progress on clinical trials and the promising market opportunities. While the stock has been under ..."
Pages
52
Language
English
Published on
20/03/23
You may also be interested by these reports :
12/05/25
Lonza’s management expressed confidence in meeting the FY guidance. Capex projects are progressing as planned, contributing positively to ...
10/05/25
Genmab reported mixed Q1 results. Strong sales growth, driven by key offerings, resulted in solid profitability. Although our model is under review, ...
09/05/25
Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of ...
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...